June 22, 2023
A Wenger Plattner team led by Oliver Künzler advised NASDAQ-listed Bio-Techne Corporation (NASDAQ:TECH) on all legal and tax aspects of the acquisition of Lunaphore Inc.
A Wenger Plattner team led by Oliver Künzler advised Bio-Techne Corporation (NASDAQ:TECH), a NASDAQ-listed global life sciences company that offers innovative tools and bioactive reagents for research and clinical medicine, on all legal and tax aspects of its acquisition of Lunaphore Inc.
The core team also included Markus Muehlemann, Benjamin Dürig, Suzanne Eckert, Martina Braun, Cristina Solo de Zaldívar, Sarah Hilber, André S. Berne, Valérie Berger, and Linda Lauterbach.
Bio-Techne expects the acquisition to be completed in the first quarter of its fiscal year 2024.
Lunaphore, founded in 2014 and headquartered in Tolochenaz, Switzerland, is a leading developer of fully automated biological solutions based on microfluidic precision technology, capable of detecting hyper-complex proteomic and transcriptomic biomarkers in tumors and other tissues with single-cell and subcellular resolution.
Congratulations to all involved!
Stay up to date and subscribe to our Newsletter.